Expanded Access Protocol to Provide Brincidofovir for the Treatment of Serious Adenovirus Infection or Disease
NCT ID: NCT02596997
Last Updated: 2022-03-14
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NO_LONGER_AVAILABLE
EXPANDED_ACCESS
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study to Assess the Safety and Efficacy of Brincidofovir in Treatment of Early Versus Late Adenovirus Infection
NCT02087306
A Phase 2a Study of IV BCV in Subjects With Adenovirus Infection
NCT04706923
A Multicenter Study to Obtain Retrospective Data for Subjects Previously Diagnosed With Adenovirus Infection to Serve as Matched Historical Controls for Study CMX001-304
NCT02420080
Expanded Access for PSV Personalized Oncolytic Viruses
NCT03529539
A Phase 3 Study of Brincidofovir Versus Valganciclovir for the Prevention of Cytomegalovirus
NCT02439957
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Brincidofovir
Up to 100mg Brincidofovir twice weekly, not to exceed a total dose of 200mg each week
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Able to swallow medication, either tablet or liquid
Exclusion Criteria
* If female, not pregnant or trying to become pregnant
2 Months
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Jazz Pharmaceuticals
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Arkansas Medical Center
Little Rock, Arkansas, United States
Children's Hospital LA
Los Angeles, California, United States
UCLA Medical Center
Los Angeles, California, United States
Children's Hospital of Orange County
Orange, California, United States
Pediatric Stem Cell Transplantation Stanford University
Palo Alto, California, United States
Stanford University
Palo Alto, California, United States
UC San Diego Moores Cancer center
San Diego, California, United States
University of California San Francisco Benioff Children's Hospital
San Francisco, California, United States
Children's Hospital Colorado
Aurora, Colorado, United States
Children's National Medical Center
Washington D.C., District of Columbia, United States
University of Florida
Gainesville, Florida, United States
All Childrens Research Institute
St. Petersburg, Florida, United States
All Children's Research Institute
St. Petersburg, Florida, United States
Emory University-AFLAC Cancer and Blood Disorder Clinic
Atlanta, Georgia, United States
Ann & Robert H. Lurie Children's Hospital of Chicago
Chicago, Illinois, United States
University of Chicago
Chicago, Illinois, United States
Children's Mercy Hospital
Kansas City, Kansas, United States
University of Louisville-Kosair Childrens Hospital
Louisville, Kentucky, United States
Children's Hospital New Orleans
New Orleans, Louisiana, United States
Brigham & Woman's Hospital/Boston
Boston, Massachusetts, United States
Michigan State/Spectrum Health
Grand Rapids, Michigan, United States
Washington University
St Louis, Missouri, United States
University of Nebraska
Omaha, Nebraska, United States
Hackensack University MC
Hackensack, New Jersey, United States
Weill Conrell Medical Center
New York, New York, United States
Morgan Stanley Children's Hospital
New York, New York, United States
Memorial Sloan Kettering
New York, New York, United States
New York Medical College-Maria Fareri Childrens hospital
New York, New York, United States
The Children's Hospital at Montefiore
The Bronx, New York, United States
New York Medical College, Maria Fareri Children's Hospital
Valhalla, New York, United States
Levine Children's Hospital
Charlotte, North Carolina, United States
Duke University Medical System
Durham, North Carolina, United States
Cincinnatti Children's Hospital
Cincinnati, Ohio, United States
Cleveland Clinic
Cleveland, Ohio, United States
Nationwide Children's Hospital
Columbus, Ohio, United States
The Childrens hospital of Philadelphia
Philadelphia, Pennsylvania, United States
Methodist University Hospital-BMT program west clinic
Memphis, Tennessee, United States
St. Jude Research Hospital
Memphis, Tennessee, United States
UT Southwestern Medical Center
Dallas, Texas, United States
Cook Children's Health Care System
Fort Worth, Texas, United States
Baylor College of Medicine-Infectious Disease
Houston, Texas, United States
University of Texas, MD Anderson Cancer Center
Houston, Texas, United States
Methodist Children's Hospital of South Texas
San Antonio, Texas, United States
University of Washington/ Seattle Children's Hospital
Seattle, Washington, United States
Fred Hutchinson Cancer Research Center
Seattle, Washington, United States
Medical College of Wisconsin
Wauwatosa, Wisconsin, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CMX001-351
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.